Bone Biologics Corp · NASDAQ:BBLG
Bone Biologics — Investor Presentation (July 2018)
19 slides from Bone Biologics's investor presentation, Jul 6, 2018
Slide 1: Regenerative Medicine for Bone
Regenerative Medicine for Bone July 6th, 20181 Confidential & Proprietary
Slide 2: Safe Harbor Statement
Safe Harbor Statement This document does not constitute or form part of an invitation or recommendation to subscribe for or purchase any securities. The distribution may be restricted by law in certain jurisdictions and persons into whose possession this document comes should inform themselves about
Slide 3: Overview
Overview Bone Biologics is redefining bone regeneration with NELL-1, a secreted, osteoinductive protein whose expression controls skeletal ossification. NELL-1 effectively induces bone formation across small and large animal models either via local implantation or intravenous delivery Confidential &
Slide 4: A Potential Breakthrough in Bone Regeneration
A Potential Breakthrough in Bone Regeneration 1 Confidential & Proprietary 4
Slide 5: Bone Biologic's Solution To Unmet Need
Bone Biologic’s Solution To Unmet Need A major challenge in orthopedic surgery is effective bone regeneration Challenges w/ rhBMPs NELL-1 Solution Rapid bone growth (egg Rapid / healthy bone growth shelling) Forms bone in target specific Cysts & less dense bone fashion without inducing forma
Slide 6: NELL-1 Product Pipeline
NELL-1 Product Pipeline 1 Clinical Discovery Pre-Clinical Phase I Phase II Phase III Indication Spine Fusion Trauma Osteoporosis Confidential & Proprietary 6
Slide 7: NELL-1 Mechanism of Action
NELL-1 Mechanism of Action rhNELL-1 binds to the Integrin a3b1 receptor (and APR3) rhNELL-1 initiates downstream intracellular signaling of Hedgehog, FAK, MSPK, ERK1/2 (increased osteoblast differentiation) and Wnt (increased osteoblasts and inhibition of osteoclasts) Osteoclast Cell BONE RESORP
Slide 8: More Than 45 Publications on NELL-1
More Than 45 Publications on NELL-1 Confidential & Proprietary 8
Slide 9: rhNELL-1: Potential Anabolic & Anti-Osteoclastic Therapy for Osteoporosis
rhNELL-1: Potential Anabolic & Anti- Osteoclastic Therapy for Osteoporosis Publication Summary Karsik, 2010 NELL-1 single-nucleotide polymorphism is associated with reduced BMD James, 2015 Nell-1 haploinsufficient mice are more prone to osteoporosis James, 2015 IV delivery of rhNELL-1 in mice with o
Slide 10: Pilot Large-Animal Study
Pilot Large-Animal Study Clinically relevant sheep study demonstrated that rhNELL-1 increases the fusion rate and quantity of bone compared to the control / sDBX Confidential & Proprietary 10
Slide 11: Strong IP Barrier
Strong IP Barrier 14 issued patents with more than 175 claims covering: Molecular Structure - Composition Manufacturing Process - NELL-1 protein expressed in mammalian & other systems Field of Use – Use for promoting bone growth Exclusive license to NELL-1 technology from UCLA for spine, t
Slide 12: Total Addressable Market
Total Addressable Market The global orthobiologic bone replacement market is approximately $3 billion ($1.7B of which is U.S. based), and is expected to grow roughly 6% a year over the next five years. Sources: Orthopedic Confidential Network News & Proprietary 12
Slide 13: Key Metrics
Key Metrics History - Where we have come from 1 • September 19th, 2014 – reverse merge into shell corporation • December 10th, 2015 – commenced trading on OTC Bulletin Board (1/27/2016 listed on OTC QB) • March 31st, 2016 – first trade on OTC QB • March 31st, 2017 – became seasoned issuer Financial
Slide 14: Product Development Milestones
Product Development Milestones Pivotal animal data FDA Nell-1 synthesized Approval IDE US US Pilot data OUS Phase I/II Phase III From large First in data data animal study Man Data Confidential & Proprietary 14
Slide 15: Value Proposition to Stakeholders
Value Proposition to Stakeholders 1 Confidential & Proprietary 15
Slide 16: Management Team
Management Team Stephen La Neve, CEO and President CEO and President Life Science Enterprises CEO and President, Etex Corp President, Becton Dickinson’s Pre-Analytical Systems President, Medtronic Spine and Biologics Executive VP, Premier Jeffrey Frelick, COO COO Life Science Enterprises
Slide 17: Board of Directors
Board of Directors Bruce Stroever Jimmy Delshad Chairman of the Board Bone Biologics / Past CEO Musculoskeletal Former Mayor and Councilman of Beverly Hills, CA Transplant Foundation Mr. Delshad brings more than ten years of elected public service to Mr. Stroever has served as Chairman of Bone Biolo
Slide 18: Building an Orthobiologic Leader
Building an Orthobiologic Leader 1 Confidential & Proprietary 18
Slide 19: www.bonebiologics.com OTC QB: BBLG
1 2 Burlington Woods Dr, Suite 100 Burlington, MA 01803 781-552-4452 www.bonebiologics.com OTC QB: BBLG Confidential & Proprietary 19